ATE513561T1 - Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien - Google Patents

Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien

Info

Publication number
ATE513561T1
ATE513561T1 AT06808431T AT06808431T ATE513561T1 AT E513561 T1 ATE513561 T1 AT E513561T1 AT 06808431 T AT06808431 T AT 06808431T AT 06808431 T AT06808431 T AT 06808431T AT E513561 T1 ATE513561 T1 AT E513561T1
Authority
AT
Austria
Prior art keywords
adjuvants
alteration
clip
balance
flu vaccines
Prior art date
Application number
AT06808431T
Other languages
English (en)
Inventor
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37897441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE513561T1 publication Critical patent/ATE513561T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT06808431T 2005-11-04 2006-11-06 Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien ATE513561T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US81247506P 2006-06-08 2006-06-08
PCT/GB2006/004136 WO2007052059A2 (en) 2005-11-04 2006-11-06 Changing th1/th2 balance in split influenza vaccines with adjuvants

Publications (1)

Publication Number Publication Date
ATE513561T1 true ATE513561T1 (de) 2011-07-15

Family

ID=37897441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06808431T ATE513561T1 (de) 2005-11-04 2006-11-06 Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien

Country Status (12)

Country Link
US (1) US20090047353A1 (de)
EP (1) EP1951300B1 (de)
JP (1) JP5363107B2 (de)
AT (1) ATE513561T1 (de)
AU (1) AU2006310340B2 (de)
CA (1) CA2628397C (de)
CY (1) CY1112895T1 (de)
DK (1) DK1951300T3 (de)
NZ (1) NZ568212A (de)
PL (1) PL1951300T3 (de)
PT (1) PT1951300E (de)
WO (1) WO2007052059A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2420829T3 (es) * 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
EP2014279A1 (de) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
EP2268309B1 (de) 2008-03-18 2015-01-21 Novartis AG Verbesserungen der herstellung von grippevirus-impstoff-antigenen
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
EP2207031A1 (de) * 2009-05-18 2010-07-14 Abbott Biologicals B.V. Hilfsstoffprüfung für Impfstoffzubereitungen
PL2569267T5 (pl) 2010-05-12 2017-10-31 Novartis Ag Ulepszone sposoby otrzymywania skwalenu
MX2020004501A (es) 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
WO2014071231A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2016001907A1 (en) * 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
ES2370937T3 (es) * 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
CN1285753A (zh) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
DE60020677T2 (de) * 1999-02-26 2006-05-04 Chiron Corp., Emeryville Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
ES2228497T3 (es) * 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante.
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
JP2004508290A (ja) * 2000-04-26 2004-03-18 バイオベクター　セラピューティクス 免疫調節における粒状ベクターの使用
CA2406100C (en) * 2000-04-28 2010-11-02 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious influenza virus
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
WO2004075829A2 (en) * 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
US20070041998A1 (en) * 2003-03-24 2007-02-22 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
CA2565500A1 (en) * 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
WO2006060710A2 (en) * 2004-12-02 2006-06-08 Becton, Dickinson And Company Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
EP1861122A1 (de) 2005-03-23 2007-12-05 GlaxoSmithKline Biologicals S.A. Zusammensetzung

Also Published As

Publication number Publication date
JP5363107B2 (ja) 2013-12-11
NZ568212A (en) 2012-03-30
AU2006310340B2 (en) 2011-02-10
EP1951300A2 (de) 2008-08-06
JP2009514842A (ja) 2009-04-09
EP1951300B1 (de) 2011-06-22
PL1951300T3 (pl) 2012-03-30
PT1951300E (pt) 2011-09-05
AU2006310340A1 (en) 2007-05-10
WO2007052059A2 (en) 2007-05-10
CA2628397C (en) 2013-08-20
WO2007052059A3 (en) 2007-08-30
US20090047353A1 (en) 2009-02-19
CA2628397A1 (en) 2007-05-10
DK1951300T3 (da) 2011-10-03
CY1112895T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
ATE513561T1 (de) Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
DK1951299T3 (da) Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
NO20023829L (no) Proteosom influensavaksine
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EA201171128A1 (ru) Оптимизированный ранний/поздний промотор в сочетании с повторной вакцинацией способствует ответу цитотоксических т- клеток против антигенов рекомбинантных вакцин, основанных на вирусе с дефицитом по репликации
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
EA200801250A1 (ru) Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе, в качестве адъюванта сплит вакцин против гриппа
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
EA201892735A1 (ru) Состав вакцины против hiv
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
RU2010129770A (ru) Вакцина против гриппа и способ ее получения
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951300

Country of ref document: EP